docetaxel · Avyxa Holdings · NDA 215813
Docivyx
Earliest generic entry, as listed · earliest of 3 marketed strengths
14 Mar 2036
Blocked by patent: US 10398785.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10398785 | drug product · sets the listed date | 14 Mar 2036 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 215813 · 001 · RLD | solution, intravenous | 20MG/2ML (10MG/ML) | 14 Mar 2036 |
| 215813 · 002 · RLD | solution, intravenous | 80MG/8ML (10MG/ML) | 14 Mar 2036 |
| 215813 · 003 · RLD | solution, intravenous | 160MG/16ML (10MG/ML) | 14 Mar 2036 |